An update on immunotherapy for melanoma

Until recently, the prospects for melanoma patients were bleak, but scientific breakthroughs have brought effective new treatment options in the form of targeted therapy with BRAF and MEK inhibitors and, most importantly, immunotherapy in the form of checkpoint inhibitors.iĀ  To date three-ipilimumab, nivolumab and pembrolizumab-have received regulatory approval for melanoma. The first to be approved …